US FDA panel rejects broad use of Pfizer coronavirus boosters in blow to Biden plan

A panel of expert outside advisers to the US Food and Drug Administration voted against broadly approving Covid-19 vaccine booster shots on Friday, instead recommending emergency use authorisation for the narrower group of older or high-risk patients.The panel voted overwhelmingly against approving boosters for Americans age 16 and older, potentially undermining the Biden administration’s plan to roll out third shots of the Pfizer/BioNTech vaccine as soon as next week.Panel members, however,…

Read the original article at South China Morning Post